The firm cut its price target to $52 from $59 on shares of the Israeli pharmaceuticals company, but said Teva stock has an "attractive" risk/reward at current levels.
Credit Suisse analysts said the sell-off in Teva shares in May mitigates most of the risk around its multiple-sclerosis drug Copaxone.
A generic version of Copaxone could be introduced in 2017, causing Teva to issue downbeat guidance after that, but most of the associated risks are already priced into the shares, the firm noted.
The company's $40.5 billion purchase of Allergan's (AGN) generic drug unit Actavis should generate synergies for Teva beginning in 2017, Credit Suisse added.
Shares of Teva were sliding in mid-morning trading on Monday.
Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
The team rates Teva Pharmaceuticals as a Hold with a ratings score of C+. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, the team also finds weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity.
You can view the full analysis from the report here: TEVA